Last reviewed · How we verify
NCT06232109
Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects
Phase 1 trial testing Fluvoxamine in Drug Drug Interaction in 50 participants. Completed in 3 July 2024.
3 July 2024
Quick facts
| Lead sponsor | Asceneuron S.A. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 22 February 2024 |
| Primary completion | 3 July 2024 |
| Estimated completion | 3 July 2024 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Fluvoxamine (FLUVOXAMINE) — full drug profile →
- Itraconazole — full drug profile →
- Paroxetine — full drug profile →
- ASN51
Conditions studied
- Drug Drug Interaction — all drugs for Drug Drug Interaction →
Sponsor
Asceneuron S.A. — full company profile →
Who can join
Adults 18 to 55, any sex, with Drug Drug Interaction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The drug-drug interaction study has been designed to investigate the effect of Fluvoxamine, Itraconazole and Paroxetine on the pharmacokinetics of ASN51
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06232109
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fluvoxamine
Trials testing the same drug.
- NCT06969287 — Mitigating Delirium With Fluvoxamine Treatment for Non-Cardiac Surgery · Phase 3 · recruiting
- NCT07359482 — sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19 · Phase 3 · not yet recruiting
- NCT06821698 — To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in Volunteers · Phase 1 · completed
- NCT05888207 — A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects · Phase 1 · completed
- NCT05874037 — Fluvoxamine for Long COVID-19 · Phase 2, PHASE3 · completed
Other Asceneuron S.A. trials
Trials by the same sponsor.
- NCT06677203 — Study of ASN51 in Adults With Early Alzheimer's Disease · Phase 2 · terminated
- NCT05725005 — PET Study of Repeated ASN51 in Healthy Volunteers · Phase 1 · completed
- NCT06390098 — Positron Emission Tomography Study in Healthy Subjects to Determine the Relationship Between Plasma Concentration and Br · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06232109 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Asceneuron S.A.
- Last refreshed: 18 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06232109.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing